• On 17 June 2026, Jazz Pharmaceuticals and AbCellera Biologics announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors, including US$56,000,000 in upfront payments and eligibility for very large potential milestones and tiered royalties.
• An interesting aspect of this agreement is that Jazz receives exclusive, worldwide development and commercialization rights program-by-program, while AbCellera focuses on discovery, early research, and potentially clinical supply using its integrated T-cell engager platform.
• We’ll now examine how this Jazz collaboration, particularly the upfront and potential milestone economics, may influence AbCellera’s investment narrative.

Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

AbCellera Biologics Investment Narrative Recap

To own AbCellera, you need to believe its antibody discovery engine and early clinical assets can eventually convert into meaningful downstream milestones and royalties, despite current losses and execution risk. The Jazz deal adds US$56,000,000 in upfront payments, which may modestly ease near term funding concerns, but the key short term catalyst remains clinical data from ABCL635 in menopause, while the biggest risk is still whether AbCellera’s internal programs can show convincing efficacy and support a path to commercialization.

Among recent announcements, the expanded AbbVie T cell engager collaboration from January 2025 looks particularly relevant, as it also centers on AbCellera’s T cell engager capabilities in oncology. Taken together with the new Jazz agreement, this reinforces the idea that external partners are willing to fund and validate AbCellera’s TCE platform as the company invests heavily in ABCL635, ABCL575, and its own integrated manufacturing buildout, potentially creating more optionality around future milestones and royalties.

Yet despite this new cash and validation from Jazz, investors should still pay close attention to the risk that AbCellera’s heavy R&D spending and reliance on internal and partnered programs could leave future revenue streams more uncertain than they might appear at first glance...

AbCellera Biologics' narrative projects $40.9 million revenue and $6.4 million earnings by 2029. This requires a 19.8% yearly revenue decline and a $150.4 million earnings increase from -$144.0 million today.

Uncover how AbCellera Biologics' forecasts yield a $10.43 fair value, a 89% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts already expected revenue to reach about US$250,300,000 by 2028 and see the Jazz deal as potentially amplifying that path, but they also highlight how rising R&D spend and less predictable partner revenue could weigh on profitability, underscoring just how differently you can view the same company and why it may be worth considering several contrasting outlooks before deciding what this new collaboration really means for you.

Explore 9 other fair value estimates on AbCellera Biologics - why the stock might be worth just $7.00!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your AbCellera Biologics research is our analysis highlighting 2 important warning signs that could impact your investment decision.
• Our free AbCellera Biologics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbCellera Biologics' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• This technology could replace computers: discover 31 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.